Modakafusp Alfa

**Semantic type:** Pharmacologic Substance

**Definition:** A proprietary preparation composed of an immunoglobulin G4 (IgG4) directed against the cell surface glycoprotein CD-38 (CD38) that is fused to an attenuated form of human interferon alpha (IFN alpha; IFNa), with potential immunomodulating and antineoplastic activities. Upon administration, modakafusp alfa specifically targets and binds to CD38 on CD38-positive tumor cells. In turn, the IFNa moiety binds to cell-surface IFN receptors, and activates IFN-mediated signal transduction pathways, which results in the transcription and translation of genes whose products may cause antiproliferative effects in CD38-positive tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies, and its expression has been correlated with poor prognosis.

**Synonyms:** - Anti-CD38-targeted IgG4-attenuated IFNa TAK-573 - Anti-CD38-targeted IgG4-attenuated IFNa TAK-573 - Anti-CD38-targeted IgG4-attenuated Interferon Alpha TAK-573 - CD38-targeted IgG4 Fused with Attenuated IFNa - MODAKAFUSP ALFA - TAK-573 - TEV-48573